8/10/2020  5:31:07 PM Chg. -0.180 Volume Bid9:55:02 PM Ask5:40:00 PM Market Capitalization Dividend Y. P/E Ratio
6.610CHF -2.65% 10,052
Turnover: 68,082.290
6.610Bid Size: 287 7.000Ask Size: 2,500 73.02 mill.CHF 0.00% -1.13

Business description

Polyphor AG is a clinical stage, Swiss biopharmaceutical company which has discovered and is developing the OMPTA (Outer Membrane Protein Targeting Antibiotics). The OMPTA are potentially the first new class of antibiotics against Gram-negative bacteria to have reached phase III stage in the last 50 years. The company's lead product, murepavadin, (POL7080) is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by WHO. Polyphor is also developing an immuno-oncology candidate, balixafortide (POL6326), which is in preparation for a pivotal trial program in combination with eribulin in patients with advanced breast cancer, and a pipeline of further preclinical antibiotics based on its OMPTA platform. POL6014, an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases outlicensed to Santhera on 14.02.2018. Polyphor is based in Allschwil near Basel/Switzerland.
 

Management board & Supervisory board

CEO
Gökhan Batur
Management board
Hernan Levett, Dr. Daniel Obrecht, Frank Weber, Franziska Müller
Supervisory board
Dr. Kuno Sommer, Bernard Bollag, Dr. Andreas Wallnöfer, Dr. Silvio Inderbitzin
 

Company data

Name: Polyphor AG
Address: Hegenheimermattweg 125,CH-4123 Allschwil
Phone: +41-61-567-1600
Fax: -
E-mail: info@polyphor.com
Internet: https://www.polyphor.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: -
IPO date: 5/15/2018

Investor relations

Name: Hernan Levett
IR phone: +41-61-567-1624
IR Fax: -
IR e-mail: IR@polyphor.com

Company calendar

CW 36 | 9/4/2020 Interim Report 2nd Quarter/6 Months
 

Main Shareholders

Freefloat
 
80.20%
Ingro Finanz AG
 
11.20%
Varuma AG
 
8.60%